Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.66 USD
-0.09 (-3.27%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Esperion Therapeutics, Inc. has a market cap of $554.46M, which represents its share price of $2.75 multiplied by its outstanding shares number of 201.62M. As a small-cap company, ESPR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ESPR 2.66 -0.09(-3.27%)
Will ESPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for ESPR
ESPR's price falls by 3.27% on September 20, though its technical setup remains stable.
Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
ESPR: HC Wainwright & Co. Reiterates Buy Rating with $16 Target | ESPR Stock News
Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost
NEXLETOL Approval in Japan Boosts Esperion (ESPR) Prospects